Hengrui 1.3 billion "shopping"!

Pharmaceutical Network News, August 27, August 26, Hengrui Pharmaceuticals announced that it has invested 100 million yuan in equity in Dalian Wanchun, and paid a total of not more than 1.
3 billion yuan in down payment and milestone payments.
Dalian Wanchun awarded Hengrui to GEF -H1 activator punabulin's joint development rights and exclusive commercialization rights in Greater China, which quickly aroused industry attention
.
The transaction between Hengrui Pharmaceuticals and Dalian Wanchun has set a record for the highest authorized transaction amount among domestic pharmaceutical companies.
This is also one of the few cases where Hengrui Pharmaceuticals introduced new drugs from outside
.
Not only Hengrui Pharmaceuticals and Dalian Wanchun, but also CSPC and Corning Jerry, Zhenbaodao and Henokang and other large pharmaceutical companies have entered into cooperation
.
The cases of "marriage" among local pharmaceutical companies may provide new ideas and models for the innovative pharmaceutical ecology of China's pharmaceutical companies
.
"Find a good medicine,"Sun flying pull over Henry innovationin Medicare to negotiate drug innovation experienced heavy volume test, with the amount of purchase after the performance fell, Hengrui Medicine stood key node in the transformation of innovative drugs, Sun flying the "second coming "In charge of Shuai Yin .
During the exchange session with investors in August, Sun Piaoyang said that the company’s problem is that all Chinese generic drugs transformation innovative drug companies will encounter problems.
Everything develops in a spiral, not a straight line; Hengrui’s business model is to find a good medicine, then do it well and deliver it to the patients to benefit the patients; try to improve yourself and master the technology, not rule out Some new technologies will also be acquired .
The cooperation with Dalian Wanchun is also regarded by the outside world as Hengrui Pharmaceuticals is leveraging local emerging pharmaceutical companies to break through innovative research and development, and it is also Sun Piaoyang's plan to implement his good medicine .
Dalian Wanchun is a local innovative pharmaceutical company.
This cooperation under the "blood capital" of Hengrui Pharmaceuticals this time lies in the potential and performance of Punabulin to a certain extent.
　　   .
Pranabrin is a "First-in-Class" immune anti-tumor drug under development by Dalian Wanchun, which has high clinical value
.
Pranabrin is a new synthetic chemical entity that can activate the immune defense protein guanine nucleotide exchange factor (GEF-H1), accelerate the maturation of dendritic cells (DC cells) and promote antigen presentation, and directly activate T cells kill tumor cells and act as the "ignition agent of the immune system"
.
In addition, Pranabrin can also prevent the damage of bone marrow neutrophils induced by chemotherapeutic drugs and achieve an early protective effect.
It is different from G-CSF (granulocyte colony stimulating factor, which can promote the proliferation and proliferation of neutrophils).
The mechanism of action of differentiation) prevents early CIN (neutropenia caused by chemotherapy)
.
This year, the NDA application for the CIN indications of pranablin has been accepted by the United States and China successively and has been granted priority review qualifications
.
In August, Pranabrin combined with docetaxel reached the primary end point of overall survival in a global phase III clinical study of 2/3-line non-small cell lung cancer patients (EGFR wild-type), and it is planned to be in the first half of 2022 Submit an NDA application for this indication
.
At the same time, Punablin is also a high-value variety
.
According to the statistics of The Lancet, the number of new cancer patients in China in recent years has reached about 4.
5 million, and the overall proportion of patients who need to prevent CIN has exceeded 10%
.
At present, G-CSF is the standard therapy for the prevention and treatment of CIN, and there is no drug with a similar mechanism of action as Pranaburin for the prevention of CIN in clinical studies
.
In China, the G-CSF market is expected to be about 7.
5 billion yuan in 2021, of which the long-acting G-CSF (used to prevent CIN) market will exceed 5 billion yuan
.
In addition, the number of newly diagnosed lung cancer patients in China exceeds 800,000, of which non-small cell lung cancer patients account for over 85%.
The current 2/3-line gene drive negative patients have fewer options and limited curative effects.
Innovative treatments are urgently needed
.
In the 2021 semi-annual report, Hengrui Medicine fully disclosed its latest product pipeline, covering the follow-up main clinical R&D pipelines of marketed innovative drugs, the main clinical R&D pipelines of innovative drugs under research, and the main clinical R&D pipelines of overseas innovative drugs.
A total of more than 240 clinical projects have been carried out" and other information, let the market feel Hengrui Medicine's new stage of innovation and internationalization determination
.
Hengrui Medicine also stated in the semi-annual report that the company urgently needs to concentrate resources to achieve rapid breakthroughs in innovation and internationalization
.
From the current point of view, in addition to increasing its own research and development, Hengrui Pharmaceuticals is also cooperating with local emerging pharmaceutical companies to break through innovation
.
  　　Accelerating the integration of local enterprises 　 　 the   　　battle for innovative resources   　　has started Hengrui has been fully accelerating cooperation with local pharmaceutical companies.
It is worth mentioning that before this cooperation with Dalian Wanchun, in February this year, it invested 20 million US dollars in Yingli The pharmaceutical industry obtained the joint development rights and exclusive commercialization rights of another anticancer drug PI3kδ inhibitor YY-20394 in the Greater China region
.
Cooperating with innovative pharmaceutical companies emerging locally is not just a choice for Hengrui Pharmaceuticals
.
Just two days ago, on August 24, Corning Jereh and CSPC announced that the two parties had signed an agreement for the development and commercialization of the anti-HER2 bispecific antibody KN026 independently developed by Corning Jereh in Mainland China.
The total transaction is The amount is 1 billion yuan
.
On May 19, 2020, Zhenbaodao Pharmaceutical announced to pay Henuo Kang a transfer fee (including tax) consisting of a milestone payment of 150 million yuan and a sales commission of 6% of the annual net sales revenue, which was developed by the latter.
Related rights and interests of blockbuster anti-influenza drugs
.
Behind the "marriage" actions of local pharmaceutical companies, on the one hand, there are hidden turbulences in the pharmaceutical market; on the other hand, it also proves that the innovation and comprehensive strength of domestic pharmaceutical companies have been continuously improved and they have excellent strength
.
At a press conference held by the Information Office of the State Council on July 27, the Ministry of Science and Technology revealed that my country’s basic research accounted for more than 6% of R&D investment for the first time, and the original innovation capability of science and technology has been greatly improved. .
In the first half of 2021, China has approved 21 innovative drugs, which has exceeded the number of innovative drugs reviewed and approved in 2020, setting a new record again
.
Nowadays, China's pharmaceutical innovation and R&D strength has jumped from the third echelon to the second echelon, and the national policy supports innovative pharmaceutical companies at multiple levels such as drug approval and listing, medical insurance access and reimbursement.
A number of local innovative pharmaceutical companies have risen, and local pharmaceutical innovations The ecology is also undergoing subtle changes
.
In the eyes of the outside world, the cooperation between large local pharmaceutical companies and innovative companies is a representative case of biotech companies realizing the commercial value of product pipelines in advance under the background of "involving" domestic innovative drugs
.
Compared with innovative pharmaceutical companies, large local pharmaceutical companies have more mature drug commercialization experience and sales network, and also have more abundant cash flow.
Through cooperation with innovative pharmaceutical companies, they can obtain cash to support the continuous development of other innovative products, and at the same time use Due to the commercialization capabilities of large pharmaceutical companies, the relevant varieties of innovative pharmaceutical companies can also obtain better market sales expectations
.
For large local pharmaceutical companies, innovative pharmaceutical companies have a richer variety of innovative products, as well as stronger early-stage R&D capabilities and talent reserves.
Cooperation with them can accelerate their transformation into innovative drugs
.
In the long run, the combination of large-scale local pharmaceutical companies and innovative pharmaceutical companies is a win-win cooperation
.
China 100 billion of Health medical market also attracted global pharmaceutical giants actively in local companies to commercialize innovative cooperation
.
Previously, CStone Pharmaceuticals announced that it would cooperate with Pfizer on c-rosoncogene 1 (ROS1) positive advanced non-small cell carcinoma (NSCLC) co-developed lorlatinib
.
In addition, Cinda Biopharmaceuticals and Eli Lilly have jointly developed the PD-1 inhibitor Sintilimab
.
As large local pharmaceutical companies also cooperate with innovative pharmaceutical companies to compete for innovation resources, the tide is rising, and domestic drug innovation is about to set off an even more fierce battle for innovation
.